Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
A multi-country analysis of COVID-19 hospitalizations by vaccination status.
Gonçalves BP, Jassat W, Baruch J, Hashmi M, Rojek A, Dasgupta A, Martin-Loeches I, Reyes LF, Piubelli C, Citarella BW, Kartsonaki C, Lefèvre B, López Revilla JW, Lunn M, Harrison EM, Kraemer MUG, Shrapnel S, Horby P, Bisoffi Z, Olliaro PL, Merson L; ISARIC Clinical Characterisation Group. Gonçalves BP, et al. Med. 2023 Nov 10;4(11):797-812.e2. doi: 10.1016/j.medj.2023.08.005. Epub 2023 Sep 21. Med. 2023. PMID: 37738979 Free PMC article.
CONCLUSIONS: These findings will inform allocation of healthcare resources in future surges as well as design of longer-term international studies to characterize changes in clinical profile of hospitalized COVID-19 patients related to vaccination history. ...
CONCLUSIONS: These findings will inform allocation of healthcare resources in future surges as well as design of longer-term internat …
More than a 'Hundred Days War': Persistent SARS-CoV-2 infection in a patient with ANCA-associated vasculitis.
Mendel A, Colmegna I, Bourque G, Rajda E, Lee TC, Gálvez JH, Vinet É, Cheng MP. Mendel A, et al. Among authors: cheng mp. J Assoc Med Microbiol Infect Dis Can. 2022 Jun 3;7(2):131-134. doi: 10.3138/jammi-2021-0033. eCollection 2022 Jun. J Assoc Med Microbiol Infect Dis Can. 2022. PMID: 36337358 Free PMC article.
RESULTS: Sequencing confirmed that all samples tested were from the same viral lineage, indicating a long-term, persistent infection rather than re-infection with a new strain. ...
RESULTS: Sequencing confirmed that all samples tested were from the same viral lineage, indicating a long-term, persistent infection …
Short Communication: Ongoing Impact of the Social Determinants of Health During the Second and Third Waves of the COVID-19 Pandemic in People Living with HIV Receiving Care in a Montreal-Based Tertiary Care Center.
Almomen A, Cox J, Lebouché B, Cheng MP, Frenette C, Routy JP, Costiniuk CT. Almomen A, et al. Among authors: cheng mp. AIDS Res Hum Retroviruses. 2022 May;38(5):359-362. doi: 10.1089/AID.2021.0186. Epub 2022 Mar 14. AIDS Res Hum Retroviruses. 2022. PMID: 35172609
Similar to what we observed during the first wave, PLWH who acquired COVID-19 during waves two and three of the pandemic often worked or lived in long-term care residences or health care settings, putting them at risk. ...
Similar to what we observed during the first wave, PLWH who acquired COVID-19 during waves two and three of the pandemic often worked or liv …
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.
Sharma A, Elharram M, Afilalo J, Flannery A, Afilalo M, Tselios C, Ni J, Ezekowitz JA, Cheng MP, Ambrosy AP, Zannad F, Brophy JM, Giannetti N, Bessissow A, Kronfli N, Marelli A, Aziz H, Alqahtani M, Aflaki M, Craig M, Lopes RD, Ferreira JP. Sharma A, et al. Among authors: cheng mp. Am Heart J. 2022 May;247:76-89. doi: 10.1016/j.ahj.2022.01.015. Epub 2022 Feb 7. Am Heart J. 2022. PMID: 35143744 Free PMC article. Clinical Trial.
We evaluated whether continuation versus discontinuation of RAASi were associated with short term clinical or biochemical outcomes. METHODS: The RAAS-COVID-19 trial was a randomized, open label study in adult patients previously treated with RAASi who are hospitalized with …
We evaluated whether continuation versus discontinuation of RAASi were associated with short term clinical or biochemical outcomes. M …
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.
Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, Yanes-Lane M, Whelan M, Perlman-Arrow S, Chen J, Rahim H, Ilincic N, Segal M, Duarte N, Van Wyk J, Yan T, Atmaja A, Rocco S, Joseph A, Penny L, Clifton DA, Williamson T, Yansouni CP, Evans TG, Chevrier J, Papenburg J, Cheng MP. Bobrovitz N, et al. Among authors: cheng mp. PLoS One. 2021 Jun 23;16(6):e0252617. doi: 10.1371/journal.pone.0252617. eCollection 2021. PLoS One. 2021. PMID: 34161316 Free PMC article.
Seroprevalence was low in the general population (median 4.5%, IQR 2.4-8.4%); however, it varied widely in specific populations from low (0.6% perinatal) to high (59% persons in assisted living and long-term care facilities). Median seroprevalence also varied by Global Bur …
Seroprevalence was low in the general population (median 4.5%, IQR 2.4-8.4%); however, it varied widely in specific populations from low (0. …
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
Ward BJ, Gobeil P, Séguin A, Atkins J, Boulay I, Charbonneau PY, Couture M, D'Aoust MA, Dhaliwall J, Finkle C, Hager K, Mahmood A, Makarkov A, Cheng MP, Pillet S, Schimke P, St-Martin S, Trépanier S, Landry N. Ward BJ, et al. Among authors: cheng mp. Nat Med. 2021 Jun;27(6):1071-1078. doi: 10.1038/s41591-021-01370-1. Epub 2021 May 18. Nat Med. 2021. PMID: 34007070 Free PMC article. Clinical Trial.
Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ). The co-primary …
Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a vir …
Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents.
Miller MA, Molina KC, Gutman JA, Scherger S, Lum JM, Mossad SB, Burgess M, Cheng MP, Chuang ST, Jacobs SE, Melendez DP, Shah DP, Zimmer A, Sohail MR, Syed S, Walker RC, Poeschla EM, Abidi MZ. Miller MA, et al. Among authors: cheng mp. Open Forum Infect Dis. 2020 Dec 30;8(2):ofaa646. doi: 10.1093/ofid/ofaa646. eCollection 2021 Feb. Open Forum Infect Dis. 2020. PMID: 33575424 Free PMC article.
Initial treatment with AmB plus posaconazole or isavuconazole (n = 28) was associated with a trend toward lower treatment failure compared with AmB (n = 21) (42% vs 64%, P = .136). CONCLUSIONS: Long-term survival with IM among HM and HCT populations remains poor. ...
Initial treatment with AmB plus posaconazole or isavuconazole (n = 28) was associated with a trend toward lower treatment failure compared w …
Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M, Flannery A, Ferreira JP, Cheng MP, Kronfli N, Marelli A, Zannad F, Brophy J, Afillalo J, Huynh T, Giannetti N, Bessissow A, Ezekowitz JA, Lopes RD, Ambrosy AP, Craig M, Sharma A. Aflaki M, et al. Among authors: cheng mp. Trials. 2021 Feb 5;22(1):115. doi: 10.1186/s13063-021-05080-4. Trials. 2021. PMID: 33546734 Free PMC article.
OBJECTIVES: The aim of the RAAS-COVID-19 randomized control trial is to evaluate whether an upfront strategy of temporary discontinuation of renin angiotensin aldosterone system (RAAS) inhibition versus continuation of RAAS inhibition among patients admitted with established COVI …
OBJECTIVES: The aim of the RAAS-COVID-19 randomized control trial is to evaluate whether an upfront strategy of temporary discontinuation of …